Prolotherapy and Sclerotherapy — CPB 0207 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0207 covering prolotherapy and sclerotherapy, effective September 26, 2025. Billing teams should audit their charge capture for CPT codes 36465, 36466, 36468, 36470, 36471, 43204, 43243, 45520, and 49185 — plus HCPCS M0076 — against the updated medical necessity criteria before submitting claims.

Quick-Reference Table

Aetna Sclerotherapy and Prolotherapy Coverage Criteria and Medical Necessity Requirements 2025

CPB 0207 Aetna draws a hard line between sclerotherapy and prolotherapy. Sclerotherapy has a defined list of covered indications. Prolotherapy does not — Aetna considers it experimental and investigational across the board.

The Aetna sclerotherapy coverage policy covers 13 specific indications. Each one carries its own clinical bar. This is not a "treat-anything-with-a-needle" policy. If your documentation doesn't match one of these indications precisely, expect a claim denial.

Here's what Aetna considers medically necessary for sclerotherapy:

Aetna also covers ultrasound-guided percutaneous cyst aspiration with sclerotherapy for symptomatic, large (4 cm or larger), simple hepatic cysts. The symptom must be abdominal pain attributed to the cyst. The ICD-10 code K76.89 applies. One absolute contraindication: communication of the cyst with the biliary tree. If that's present, sclerotherapy is off the table entirely. Document this clearly in the medical record.

The Ongley solution (also called P2G) is classified as a proliferant solution under this policy. Sodium tetradecyl sulfate (Sotradecol) is classified as a proliferant solution for sclerotherapy of varicose veins. Know which solution your provider is using — it matters for how claims are coded and potentially denied.

Prior authorization requirements vary by plan. Check the specific Aetna plan your patient is enrolled in before scheduling sclerotherapy for any of these indications. High-dollar procedures like hepatic cyst sclerotherapy and vascular malformation treatment are the most likely to trigger a prior auth requirement.

Aetna Prolotherapy and Sclerotherapy Exclusions and Non-Covered Indications

Prolotherapy is the real story here. Aetna considers prolotherapy — billed under HCPCS M0076 — experimental and investigational for all indications. That includes joint sclerotherapy and reconstructive ligament therapy. No exceptions are listed in the policy.

This matters if your practice treats musculoskeletal pain. Providers who use dextrose injections for ligament laxity, low back pain, or joint instability will not get reimbursement from Aetna under this policy. The CPT codes in the 20550 and 20600 series (arthrocentesis and tendon sheath injections) appear in the policy, but they are listed under "other CPT codes related to the CPB" — not under covered sclerotherapy indications.

The implication is direct. If your billing team submits claims for prolotherapy to Aetna using these codes, you are looking at claim denial. No amount of documentation will overcome a blanket experimental designation. Redirect those patients to appeals or alternative treatment pathways before the claim goes out.

Perineural dextrose prolotherapy also has no specific billing code under this policy. The policy notes M0076 as the closest code, but it maps to a non-covered indication. Do not bill perineural dextrose injections to Aetna and expect payment.

Coverage Indications at a Glance

Aetna Sclerotherapy Billing Guidelines and Action Items 2025

1. Audit your active Aetna claims for prolotherapy codes before September 26, 2025.
Any claim with HCPCS M0076 or CPT codes in the 20550 and 20600 series billed as prolotherapy should be flagged. These will not be paid. Pull your aging report and stop any pending submissions.

2. Map every sclerotherapy claim to a specific covered indication — not just a diagnosis code.
Aetna's coverage policy is indication-specific. A diagnosis of venous insufficiency alone is not enough. Your documentation must show which indication applies and that clinical criteria are met.

3. Document conservative treatment failure before billing for Morton's neuroma or hemorrhoids.
Aetna is explicit. For Morton's neuroma, you need failed orthotic use and failed corticosteroid injections on record. For hemorrhoids, document failed nitroglycerin, failed lidocaine-hydrocortisone, and failed hydrocortisone. Missing any one of these creates a medical necessity gap that will trigger denial.

4. Verify hepatic cyst claims include size and symptom documentation.
The cyst must be 4 cm or larger. The patient must have abdominal pain attributed to the cyst. And the record must rule out biliary communication — that is an absolute contraindication to sclerotherapy. If you bill CPT 49185 for hepatic cysts without this documentation, the claim will fail.

5. Check prior authorization requirements plan by plan before scheduling.
Aetna plan variation is real. The coverage policy sets the floor, but individual plans add prior auth layers on top. For high-cost procedures — hepatic cyst sclerotherapy, vascular malformation treatment, and esophageal variceal sclerotherapy — check prior auth status before the procedure date, not after. A missed prior auth is a denial you cannot bill the patient for.

6. Update your ICD-10 pairing logic in your charge capture system.
Several indications in CPB 0207 have narrow ICD-10 code ranges. For venous ulcerations, the valid codes span I87.311 through I87.339 and I87.8. For hemorrhoids, K64.0 through K64.9 are all valid. For Morton's neuroma, use G57.60–G57.63. Build these pairings into your charge capture templates so your coders aren't guessing at the point of entry.

7. If your practice does both prolotherapy and sclerotherapy, separate your workflows now.
Prolotherapy billing guidelines under this policy lead to a dead end with Aetna. Sclerotherapy billing has a clear path — but only for specific indications. Mixing the two in your charge capture or documentation workflow creates denial risk for both. Keep them separate.

If your practice has significant volume in musculoskeletal prolotherapy for Aetna patients, talk to your billing consultant and compliance officer before the September 26, 2025 effective date. The financial exposure from M0076 denials can add up fast, and a proactive appeal strategy beats a retroactive one.

CPT, HCPCS, and ICD-10 Codes for Prolotherapy and Sclerotherapy Under CPB 0207

Covered CPT Codes (When Medical Necessity Criteria Are Met)

Other CPT Codes Related to CPB 0207 (Context-Dependent — Verify Indication)

Not Covered / Experimental Codes

Key ICD-10-CM Diagnosis Codes

This policy includes 367 ICD-10-CM codes in total. The full code set is available at the Aetna CPB 0207 source document.